HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(10 sites)

United States

Quest Clinical Research, San Francisco, California

CAN Community Health Fort Lauderdale, Fort Lauderdale, Florida

Midway Immunology and Research Center (MIRC), Ft. Pierce, Florida

CAN Community Health Miami Gardens, Miami Gardens, Florida

Midland Medical, Oakland Park, Florida

Orlando Immunology Center, Orlando, Florida

CAN Community Health Sarasota, Sarasota, Florida

CAN Community Health Las Vegas, Las Vegas, Nevada

The Rockefeller University, New York, New York

The Crofoot Research Center, Inc., Houston, Texas